

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

April 28, 2023

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

She-Chia Jankowski, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Mark R. Conaway, PhD

Professor, Division of Translational Research and
Applied Statistics
Department of Public Health Sciences
The University of Virginia School of Medicine
Charlottesville, Virginia

Jorge A. Garcia, MD, FACP

(Chairperson)
Chief, Division of Solid Tumor Oncology
George & Edith Richman Distinguished Scientist Chair
Professor of Medicine and Urology
GU Medical Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Christopher H. Lieu, MD

Associate Professor of Medicine
Associate Co-Director for Clinical Research
Director, Gastrointestinal Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado

Ravi A. Madan, MD

Senior Clinician,
Head, Prostate Cancer Clinical Research Section
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute, National Institutes of Health
Bethesda, Maryland

David E. Mitchell

President, Patients For Affordable Drugs
Bethesda, Maryland

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC) Norris
Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Ashley Rosko, MD

Associate Professor
Division of Hematology
Medical Director Oncogeriatric
The Ohio State University Comprehensive Cancer
Center
Columbus, Ohio

Neil Vasan, MD, PhD

Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 28, 2023

MEETING ROSTER (cont.)

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Michael Bui, DDS, JD

(Acting Industry Representative)

Senior Vice-President, Global Regulatory Affairs
Pyxis Oncology
Boston, Massachusetts

TEMPORARY MEMBERS (Voting)

Rhonda Bitting, MD

Staff Oncologist, Durham VA Healthcare System
Associate Professor of Medicine, Duke University
Durham, North Carolina

Julie Graff, MD

Staff Oncologist
VA Portland Health Care System
Professor of Medicine
Oregon Health & Science University
Portland, Oregon

Andrea L. Harzstark, MD

Co-Director, Kaiser Permanente National
Genitourinary Oncology Program
Assistant Director, KP Oncology Clinical Trials
Kaiser Permanente Northern California, San
Francisco Campus
San Francisco, California

Terrence M. Kungel, MBA

(Patient Representative)
Chairman Emeritus
Maine Coalition to Fight Prostate Cancer
Woolwich, Main

Brian I. Rini, MD, FASCO

Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Ingram Professor of Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 28, 2023

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Paul Kluetz, MD

Deputy Director, OCE
Supervisory Associate Director (Acting)
OOD, OND, CDER, FDA

Laleh Amiri-Kordestani, MD

Director
Division of Oncology 1 (DO1)
OOD, OND, CDER, FDA

Daniel Suzman, MD

Deputy Director
DO1, OOD, OND, CDER, FDA

Chana Weinstock, MD

Supervisory Associate Director (Acting)
DO1, OOD, OND, CDER, FDA

Jaleh Fallah, MD

Clinical Reviewer
Genitourinary Malignancies
DO1, OOD, OND, CDER, FDA